KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. Show more

200 Crossing Boulevard, Framingham, MA, 01702, United States

Biotechnology

Healthcare

Market Cap

995.3M

52 Wk Range

$9.83 - $21.30

Previous Close

$19.43

Open

$19.85

Volume

987,598

Day Range

$19.24 - $19.95

Enterprise Value

846.9M

Cash

309.2M

Avg Qtr Burn

N/A

Insider Ownership

1.71%

Institutional Own.

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
EKTERLY® (sebetralstat) Details Hereditary angioedema	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sebetralstat (KVD900) (film coated) Details Hereditary angioedema	sNDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KVD824 (plasma kallikrein enzyme inhibitor) Details Hereditary angioedema , Rare diseases, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KVD001 (IVT) Details Diabetic macular edema, Frontotemporal dementia with C9orf72 mutation, Dementia, Diabetes	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.